Photo: Zero Creatives GmbH/GettyImages
AI-enabled clinical trial simulation company QuantHealth announced a strategic investment from Sanofi Ventures, the venture capital division of biopharmaceutical company Sanofi, bringing its total funds raised to $30 million.
Cris De Luca, partner at Sanofi Ventures, will join QuantHealth's board of directors as an observer.
WHAT IT DOES
QuantHealth's AI-powered clinical simulator predicts how an individual in a clinical trial will respond to treatment. The aim is to assist pharmaceutical companies in improving their clinical trial design.
According to QuantHealth, its trial design teams virtually test thousands of clinical hypotheses, assessing the impact of various inclusion/exclusion criteria, treatment, and control arms and endpoints.
The platform also allows the trial design team to modify any protocol parameter and assess its clinical, operational and commercial impact.
QuantHealth's AI-based indication selection module predicts the efficacy and safety of drugs across various medical conditions and diseases.
The company will use the funds to expand its patient-level simulations and digital twin technologies in the drug development space.
"Sanofi is at the forefront of digital transformation in pharma and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development," Orr Inbar, CEO and cofounder of QuantHealth, said in a statement.
Sanofi Venture's De Luca said QuantHealth has the ability to change how clinical trials are designed and optimized.
"Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team," De Luca said in a statement.
MARKET SNAPSHOT
In May, QuantHealth unveiled its large real-world drug model, saying it can process and utilize data from more than 100 million patients and billions of therapeutic data points in a single simulation.
That same month, Viz.ai partnered with Regeneron and Sanofi to deploy and study an AI-enabled workflow tool for the treatment of COPD.
Through the partnership, Sanofi and Regeneron supported the company's investigation of its Viz COPD Module, which employs AI and electronic health record data, using natural language processing to detect and manage high-risk COPD patients.
In 2024, OMNY Health, which helps hospitals monetize operational data, launched an AI-powered platform for health technology companies to leverage its data on more than 75 million patients.
QuantHealth added OMNY's data to its existing AI technology, which is trained on a dataset of 350 million patients. The collaboration helped QuantHealth's pharmaceutical partners accelerate drug development through simulated clinical trials and predict clinical trial outcomes, patient responses and drug efficacy.
That same year QuantHealth added additional funding to its Series A round, bringing its total Series A raise to $17 million.
Accenture Ventures, a CRO firm and additional investors contributed to the additional Series A investment.
In 2023, QuantHealth scored $15 million in a Series A funding round co-led by Pitango HealthTech and Bertelsmann Investments, bringing its total raise to $20 million.
The company said it used the funds to develop its product, grow its platform, expand its offerings commercially and evaluate use cases beyond clinical trials, including early research and development and regulatory support.
Zucara Therapeutics announced that Sanofi made a strategic investment in the company as part of its $20 million Series B financing. Sanofi received an exclusive right of first negotiation.
Proceeds from the financing funded Zucara's Phase 2a trial of the effect of ZT-01 on nocturnal hypoglycemia events in Type 1 diabetes ("T1D") mellitus ("ZONE") and the nonclinical activities to support a once-weekly version of ZT-01.
